Big Biotech Emerges as Late-Stage Licensee
Executive SummaryThe sheer size of today's Big Pharmas has created a problem when it comes to licensing late-stage products; many of those available simply don't have large enough revenue projections to significantly contribute to the Big Pharmas' earnings. But larger biotechs, which don't necessarily need blockbusters to grow earnings, seem to have begun to fill the gap.
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.